Table 3 Treatment regimens and clinical outcomes of carba-NS Enterobacterales and carba-NS Acinetobacter baumannii complex meningitis
Antimicrobial therapies | Total, n | Clinical success, n (%) | Clinical failure, n (%) | P |
|---|---|---|---|---|
Carba-NS Enterobacterales meningitis (n = 60) | ||||
 Aminoglycoside-based vs. non-aminoglycosides | ||||
  Aminoglycoside-based therapy | 29 | 20 (69.0) | 9 (31.0) | 0.019 |
  Non-aminoglycosides therapy | 31 | 12 (38.7) | 19 (61.3) |  |
 SXT-based vs. non-SXT | ||||
  SXT-based therapy | 11 | 9 (81.8) | 2 (18.2) | 0.036 |
  Non-SXT therapy | 49 | 23 (46.9) | 26 (53.1) |  |
 Fosfomycin-based vs. non-fosfomycin | ||||
  Fosfomycin-based therapy | 17 | 10 (58.8) | 7 (41.2) | 0.592 |
  Non-fosfomycin therapy | 43 | 22 (51.2) | 21 (48.8) |  |
 Carbapenem-based vs. aminoglycoside-based therapy | ||||
  Carbapenem-based (without aminoglycosides) therapy | 18 | 4 (22.2) | 14 (77.8) |  |
  Aminoglycoside-based (without carbapenems) therapy | 7 | 5 (71.4) | 2 (28.6) | 0.007 |
  Carbapenems + aminoglycoside-based | 22 | 15 (68.2) | 7 (31.8) |  |
Carba-NS A. baumannii complex meningitis (n = 82) | ||||
 Tetracycline-based vs. non-tetracyclines | ||||
  Tetracycline-based therapy | 35 | 22 (62.9) | 13 (37.1) | 0.044 |
  Non-tetracycline therapy | 47 | 19 (40.4) | 28 (59.6) |  |
 Sulbactam-based vs. non-sulbactam | ||||
  Sulbactam-based therapy | 40 | 21 (52.5) | 19 (47.5) | 0.659 |
  Non-sulbactam therapy | 42 | 20 (47.6) | 22 (52.4) |  |
Carbapenem-based vs. sulbactam-based therapy | ||||
  Carbapenem-based (without sulbactam) therapy | 29 | 11 (37.9) | 18 (62.1) |  |
  Sulbactam-based (without carbapenems) therapy | 23 | 13 (56.5) | 10 (43.5) | 0.409 |
  Carbapenems + sulbactam-based therapy | 17 | 8 (47.1) | 9 (52.9) |  |